MarketInOut Stock Screener Log In | Sign Up
 

NewAmsterdam Pharma Co N.V.

NASDAQ • Healthcare • Biotechnology • Quote as of 08/26/2026 11:06
NewAmsterdam Pharma Co N.V. stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,331.5 mln
Float82.90 mln
Earnings Date11/11/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

71.37
Highly suspicious

1-Year Forecast

51.97
Transformational upside

Relative Strength

26 / 100
Underperforming

Debt / Equity

0.00
Debt-free

ROE

-37.21
Deeply negative

Business Description

NewAmsterdam Pharma is a Netherlands-based drug development company focused on treating heart and metabolic conditions. Its lead drug, Obicetrapib, is a low-dose oral pill designed to reduce harmful cholesterol levels, currently being tested in multiple clinical trials both on its own and alongside another cholesterol-lowering agent. The company is also exploring whether Obicetrapib may offer benefits for patients with Alzheimer's disease.

Key Fundamentals

EPS-2.16
ROE-37.21
RPS0.06
ROIC-211
ROA-34.07
EBITDA, mln-244
EV / EBITDA-10.65
EV / EBIT-10.64
Revenue, mln7.12
EV / Revenue365

Financial Strength

Altman Z-Score27.01
Piotroski F-Score 3 / 9
Beneish M-Score71.37
1-Year Target Price51.97
Short Ratio10.49
Short % of Float9.93

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.75% 12 / 100   
1 Month -3.9% 20 / 100   
2 Months -20.26% 16 / 100   
6 Months -23.19% 19 / 100   
1 Year 8.87% 54 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us